Lysogene’s Board of Directors is composed of accomplished leaders from the healthcare industry who bring their expertise in science, drug development, commercialization and strategy to developing and expanding our gene therapy programs.
Annette V. Clancy is Chair of Lysogene's Board of Directors.
Ms Clancy has over 15 years’ experience in business development having served as Head of Global Transactions and Alliance Management at GlaxoSmithKline (GSK) up until 2008 where she was responsible for executing innovative deals ranging from early drug discovery partnerships, to global commercial alliances and mergers and acquisitions. Prior to her role in business development, Ms. Clancy held a number of positions in clinical research, R&D project management and commercialization within GSK, developing a broad range of commercial and business expertise. Ms. Clancy is currently Senior European Advisor to the life science team of Frazier Healthcare. In addition to this role, Ms. Clancy has held a number of non-executive board positions on private and public European biotech companies and she currently serves as Chair of the Board at Genable Technologies Ltd (Ireland) and Obseva Ltd (Switzerland) and is a Non-Executive Director on the Board of SOBI Inc (Sweden).
Ms. Clancy has a B.Sc. (Hons) Pharmacology from Bath University and is based in London, UK.
Rafaèle Tordjman, MD, PhD, is a venture capitalist since 2001 with more than 15 years of experience, specialized in life sciences investments. She joined Sofinnova Partners in 2001, an independent venture capital firm based in Paris, and served as a Managing Partner until February 2017. Prior to this, she worked as a research scientist at the Institut National de la Recherche Médicale (INSERM) in Cochin Hospital, Paris. Before joining INSERM, she was a medical doctor specializing in clinical haematology and internal medicine. She obtained her PhD, with high honours, in haematopoiesis and angiogenesis from the University Paris VII followed by a post-doctoral fellowship in immunology. Rafaèle obtained her medical degree and her specialization in Haematology and Internal Medicine as a five-year fellow in Paris University Hospitals. She also participated in the “Young Manager Program” at INSEAD (France, in 2002). She has invested in and is on the board of Nucana Biomed, ObsEva [OBSV] – which went public on Nasdaq, Lysogene [LYS] – which went public on EuroNext Paris. She has also invested in and was on the board of Enyo Pharma, MedDay, Ascendis [ASDN] – listed on Nasdaq, DBV technologies[DBV] – listed on Nasdaq and EuroNext, Flexion Therapeutics [FLXN] – listed on Nasdaq, Corevalve before it was sold to Medtronic, Endoart before it was successfully sold to Allergan Inc, of Preglem before the latter was successfully sold to Gedeon Richter, and HBI Ltd before being acquired by Meda.
Rafaèle is also founder and Chairman of the not for profit association for promoting innovative healthcare driven by women, W.I.T.H (Women Innovating Together in Healthcare – http://with-association.com/).
David Schilansky is a non-Executive Member of Lysogene’s Board of Directors
Mr. Schilansky, currently Deputy CEO and Chief Operating Officer of DBV Technologies (Euronext: DBV; NASDAQ: DBVT), has 20 years of leadership experience in the field of biotechnology and finance. DBV Technologies is a late clinical-stage specialty biopharmaceutical company, for which Mr. Schilansky oversees the company’s strategic implementation. He was appointed to this role in January 2015 after serving as the Chief Financial Officer from 2011. He is a member of DBV Technologies’ Executive Committee. Previously, Mr. Schilansky held various senior positions at Ipsen Pharma, including Interim Chief Financial Officer. Earlier in his career, he worked at Thomson Inc. (now Technicolor S.A.) as co-head of investor relations and at Warburg Dillon Read (now UBS) in mergers and acquisitions.
Mr. Schilansky received a master’s degree from the University of Paris Dauphine and a post-graduate degree from the Imperial College London.
Mr Peter Lichtlen is a non-Executive, independent member of Lysogene's Board of Directors.
Dr. Peter Lichtlen was Chief Medical Officer at Sucampo Pharmaceuticals Inc. until the company’s acquisition by Mallinckrodt Pharmaceuticals earlier this year and has 18 years of leadership experience in the field of biotechnology.
Prior to joining Sucampo, Dr. Lichtlen was at ESBATech AG (acquired by Alcon/Novartis in 2009), which he joined in 2000. At ESBATech, Dr. Lichtlen served as Medical Director/Head Clinical Research and Development and was a member of its senior management team, from 2004 to 2010. Dr. Lichtlen also co-founded Numab AG, a Swiss biotechnology company that develops antibody-based therapeutics, where he remains a member of the Board of Directors and Chief Medical Officer. Dr. Lichtlen also currently serves on the scientific advisory board of Apidel SA, a drug delivery company.
Dr. Lichtlen is a member of the Swiss Medical Association (FMH) and the Swiss Association of Pharmaceutical Professionals (SwAPP), the author of various peer-reviewed articles, and the holder of several patents. Dr. Lichtlen earned a Bachelor’s Degree in business administration, and doctorate degrees in medicine and molecular biology at the University of Zurich.